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ICU = intensive care unit; MRSA = methicillin-resistant Staphylococcus aureus; SDD = selective decontamination of the digestive tract; VRE = 
vancomycin-resistant entercocci.
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After its first application in intensive care patients in 1984,
selective decontamination of the digestive tract (SDD) has
been the subject of intense debate between intensivists,
infectious disease specialists, microbiologists and
methodologists. In 2000, a group of Dutch physicians
summarized the scientific evidence on the effects of SDD [1].
They concluded that SDD was associated with a reduction in
the incidence of intensive care unit (ICU)-acquired respiratory
infections, but improvements in patient survival had not been
demonstrated in individual studies. Although several meta-
analyses suggested a 20% reduction in ICU mortality, these
results should be confirmed in randomized, and preferably
double-blind, trials. Significant improvements in outcome with
regard to secondary outcomes such as reductions in the
duration of ventilation and ICU stay, overall antibiotic use and
cost-effectiveness had not been demonstrated. Moreover, the
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Abstract
Although many studies have shown beneficial effects of SDD on the incidence of respiratory tract
infections, SDD did not become routine practice because mortality reduction was not demonstrated in
individual trials, beneficial effects on duration of ventilation, ICU stay or hospital stay were not
demonstrated, cost-efficacy had not been demonstrated, and selection of antibiotic resistance was
considered a serious side-effect. A recent study has now shown improved patient survival and lower
prevalence of antibiotic resistance in patients receiving SDD. Why could this study show mortality
reduction, where all others studies had failed before? And do the microbiological data unequivocally
prove protective effects of SDD on emergence of antibiotic resistance? Interestingly, the reported
mortality reductions exceeds even the most optimistic predictions from previous meta-analyses, but a
clear explanation is not yet evident. The data on antibiotic resistance, however, are rather superficial
and do not allow to interpret the underlying epidemiological dynamics. Therefore, the recent findings
are provocative and shed new light on the SDD issue, warranting studies confirming its beneficial
effects but also addressing several important aspects related to study design.
Keywords bacterial resistance, intensive care unit acquired infections, pneumonia, selective decontamination of
the digestive tract, ventilator-associated pneumonia
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relative importance of the individual components of SDD had
not been determined. Finally, selection and emergence of
antibiotic-resistant microorganisms was considered an
important drawback of the routine use of SDD. Based on
these arguments, the routine use of SDD was not advised.
What has changed since then?
The first randomized trial on SDD that showed, on intention-
to-treat analysis, an impressive reduction in both ICU
mortality and hospital mortality for patients receiving SDD
has recently been presented [2]. SDD consisted of
nonabsorbable antibiotics in the oral cavity and the rest of
the digestive tract, systemic prophylaxis with cefotaxime for
4 days intravenously, and nebulization with tobramycin or
amphotericin B when tracheal colonization with Gram-
negative rods or yeasts occurred. A total of 934 medical and
surgical patients were included in the trial, and SDD was
associated with a relative reduction of ICU mortality of 36%.
This is the highest mortality reduction reported in any
individual trial and even exceeds the most positive
predictions calculated from meta-analyses for mixed
populations. Moreover, patients receiving SDD had a shorter
length of ICU stay and fewer patients became colonized with
antibiotic-resistant Gram-negative bacteria. Because the
study has as yet only been presented in abstract form, it is
difficult and premature to draw firm conclusions already.
However, the researchers ought to be congratulated with
their impressive achievement. Why did this study succeed,
where over 30 randomized trials had failed before?
Structural differences between the two study groups are, at
first sight, unlikely and, when compared with other studies,
the ICU mortality rate in the control group is similar to earlier
reported mortality rates. The beneficial effects on patient
outcome, however, cannot be explained solely by the larger
size, and hence larger power, of the present study. The 36%
relative risk reduction of ICU mortality is much larger than in
other studies. This reduction in mortality was not restricted to
the intensive care period, but persisted throughout the whole
period of hospital stay. In fact, a mortality reduction of this
magnitude would have resulted in statistically significant
mortality differences in several of the earlier studies. It is
important to understand the underlying factors leading to this
significant mortality reduction to assess the association with
systemic or local administered antibiotics.
Importantly, the randomization design in the discussed study
was different from the design used in previous studies.
Instead of randomizing consecutive patients within a single
unit, patients were randomized to either one of two ICU units
and SDD was applied to all patients in the so-called SDD
ward [2]. It has been argued before that randomization within
a single unit would reduce the potential efficacy of SDD
(effect modification): decontaminated patients would
‘protect’ nondecontaminated patients from acquired
colonization and subsequent infection, and vice versa.
However, to what extent can cross-acquisition of
microorganisms affect patient outcome? Only a fraction of all
colonized patients will develop an infection, and attributable
mortality due to ICU-acquired infections is far from 100%.
This implies that the role of cross-transmission in infections
must have been extremely high in order to create a mortality
difference, and can therefore not be considered as an
explanation. In this regard, it is unfortunate that the
investigators did not use a crossover design. Unmeasured,
and perhaps unexpected, structural differences between the
two units can therefore not be ruled out.
The dynamics of colonization and infection with antibiotic-
resistant pathogens in the ICU are complicated. The
proportion of colonized patients can change through
admission of patients that are already colonized. In addition,
treatment with antibiotics may create resistance by
influencing molecular biological mechanisms or selection of
pre-existing, but so far undetectable, resistant flora. As the
latter events can occur within a patient, they could be
considered endogenous colonization. Antibiotic resistance
may result from mutations of endogenous chromosomal
genes, from the acquisition of resistant genes or from a
combination of both events. Nontransferable resistance
arises primarily through point mutations in genes encoding
the antibiotic target (e.g. β-lactams) or by deregulated
expression of a regular process (e.g multidrug efflux pumps,
inducible β-lactamases). The frequency of these events
depends on the antibiotic pressure, the duration of the
therapy and the microorganism.
The first mechanism (resistance through mutations) is
relevant for resistance to β-lactam antibiotics
(e.g. cephalosporins and carbapenems) and quinolones
(e.g. ciprofloxacin), but is of no relevance for resistance
based on large genetic elements such as vancomycin
resistance in enterococci and methicillin resistance in
Staphylococcus aureus. Selection of pre-existing flora is
relevant for all antibiotic-resistant microorganisms. Finally,
antibiotic resistance emerges through spread from patient to
patient, usually via the hands of health care workers, which
has been called exogenous colonization. The likelihood of
cross-transmission is not a linear process, but is influenced
by nonadherence of health care workers to hygienic
measures and by the proportion of patients colonized with
resistant pathogens (i.e. colonization pressure) [3]. An
increase in the proportion of the patients being colonized will
amplify the risks for cross-transmission.
How can SDD have influenced the dynamics
of colonization with antibiotic-resistant
microorganisms?
The finding that SDD was not associated with increased
colonization with methicillin-resistant S. aureus (MRSA) is not
surprising in an ICU located in a Dutch hospital. During the
study period there was no introduction of MRSA; in addition,
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antibiotic treatment in individual patients, therapeutically or
for SDD, will not change a methicillin-susceptible S. aureus
into MRSA. The latter also holds true for vancomycin-
resistant entercocci (VRE). In contrast to the situation with
respect to MRSA, however, approximately 5% of Dutch
patients are colonized with VRE on admission [4]. Recent
findings suggest that nosocomial spread and outbreaks with
VRE are mainly caused by a specific genogroup of
Enterococcus faecium characterized by several potential
virulence factors [5]. Only two outbreaks with this genotype
of VRE have so far occurred in The Netherlands. So, without
introduction (or presence) of this strain, SDD will probably
not contribute to its emergence.
Resistance to tobramycin is usually plasmid based, whereas
resistance to imipenem and quinolones mainly results from
chromosomal mutations. All these events (especially
chromosomal mutations) can occur during antimicrobial
therapy. For correct interpretation of the resistance data of
this study [2], it is essential to determine the relative impacts
of introduction of resistant strains, of endogenous and
exogenous colonization of resistant microorganisms, and of
resistance genes. Differences in introduction in either of both
wards can be excluded by comparison of colonization rates
on admission. Discriminating endogenous and exogenous
colonization rates should be performed by genotyping
isolates and by investigating horizontal gene transfer
associated with resistance.
How could the differences in colonization
with antibiotic-resistant Gram-negative
bacteria be explained?
First, a higher therapeutic use of intravenous antibiotics in the
control population could indeed have created a higher
selective pressure for pre-existent resistant bacteria or may
have induced more mutations leading to resistance.
Second, SDD may have decreased the total bacterial burden,
thereby reducing the colonization pressure and, with equal
levels of adherence to infection control measures, reduced the
possibilities for clonal spread. This would support the use of
SDD to control outbreaks of antibiotic-resistant
microorganisms as reported previously [6]. However, it is also
possible that there was clonal spread of resistant bacteria in
the control ward, whereas tobramycin-resistant bacteria in the
non-SDD ward were polyclonal, due to increased selection
induced by SDD. If so, the conclusion that SDD prevents
emergence of resistance no longer holds true. As adherence
to infection control practices was not measured, it is unknown
if both units were comparable in this regard. Again, a crossover
design could have excluded this possibility. And if clonal
spread would have been demonstrated, the question whether
enforcement of adherence to infection control practices,
without implementation of SDD, could have prevented cross-
transmission of pathogens also remains to be determined.
Third, adherence to infection control measures may indeed
have been higher in the SDD ward. It is well known that any
intervention may, unwillingly, change clinical practice. Just
emphasizing the correct use of SDD may have improved
compliance with hygienic measures. In fact, this indirect
effect of SDD on the awareness of health care workers is
frequently put forward as one of the principles of the SDD
concept, but has never been quantified. Its contribution to
the overall results therefore remains undetermined.
Firm conclusions cannot be drawn from a study published in
abstract form only. However, the results of the latest SDD
study [2] are important and shed new light on a long-lasting
discussion. As for generalization, this impressive mortality
reduction should be confirmed in subsequent trials, but it is
evident that, from now on, patient survival in the ICU and
preferably in hospital should be the primary endpoint of such
studies. Also, the design of the study deserves further
attention. Randomization of multiple wards in a crossover
design is probably to be preferred. In addition, the relative
benefits in different patient groups (trauma, surgical or
medical, or with low, intermediate or high Acute Physiology
and Chronic Health Care Evaluation II scores) should be
determined. Moreover, the questions of which part of SDD is
most efficient and whether, for example, oropharyngeal
decontamination would have the same effects remain to be
established. Finally, the role of intravenous prophylaxis, or
better pre-emptive therapy, with intravenous cefotaxime has
not been elucidated.
The findings with regard to the role of SDD to prevent the
emergence of antibiotic resistance are challenging, but too
many questions regarding the epidemiology of these bacteria
remain unanswered to draw firm conclusions. Also, in terms
of development of resistance, the time frame of the study was
probably much too short. In hematology departments in The
Netherlands, where SDD has now been used for more than
15 years, resistant enteric bacteria have started to emerge
only recently [7,8]. Importantly, prevalence of antibiotic
resistance in The Netherlands is exceptionally low when
compared with most other European and American countries.
As a result, the selective effects of antibiotics, both topically
and systemically administered, may be completely different in
other settings. Therefore, extrapolation of the resistance
findings to ICUs in other countries may be dangerous. For
now, old concepts on the interaction between antibiotic use
and emergence of antibiotic resistance remain undisputed:
“the more you use it, the sooner you loose it”. Nevertheless,
antibiotics achieve more than causing resistance, and the
clinical benefits of SDD will decide on their fate in intensive
care patients.
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